[0001] Formulation of liposomal vesicles in aqueous vehicles with tear film characteristics. The present invention addresses the preparation of a pharmaceutical liposomal system in an aqueous solution that incorporates a substance or polymer with mucomimetic and/or mucoadhesive properties and that, owing to its components and characteristics, can replace the precorneal film. This invention is applicable to the areas of pharmacy and medicine.
1. Ophthalmic composition intended to act as replacement of the precorneal film, characterized in that it contains liposomal vesicles of neutral or negatively-charged phospholipids as hydrophilic polar phase and non-polar lipids, both vehiculized in aqueous solutions which contain mucin or substances with properties similar to mucin or mucoadhesive polymers. 2. The ophthalmic composition of claim 1 which contains mucoadhesive polymers such as hyaluronic acid, cellulose derivatives, chondroitin sulphate, chitosan, colominic acid, thiolic derivatives (or another similar component). 3. The ophthalmic composition of claim 1 which contains a substance with mucomimetic properties. 4. The ophthalmic composition of claim 1 which contains neutral lipids and low-polarity lipids such as waxes, cholesterol esters, triglycerides, free fatty acids and hydrocarbons. 5. The ophthalmic composition of claim 1 which contains lipocalins. 6. The ophthalmic composition of claim 1 which contains vitamin A. 7. The ophthalmic composition of claim 1 which contains sodium, potassium, calcium, chloride and bicarbonate ions 8. The ophthalmic composition of claim 1 which contains vitamin C. 9. The ophthalmic composition of claim 1 which contains lactoferrin. 10. The ophthalmic composition of claim 1 which contains albumin or pre-albumin. 11. The ophthalmic composition of claim 1 which contains immunoglobulin A (IGA). 12. The ophthalmic composition of claim 1 which contains epithelial growth factor (EGF). 13. The ophthalmic composition of claim 1 which contains beta transforming growth factor (TGF-β). 14. The ophthalmic composition of claim 1 which contains acidic fibroblast growth factor (aFGF). 15. The ophthalmic composition of claim 1 which contains basic fibroblast growth factor (bFGF). 16. The ophthalmic composition of claim 1 which contains antiproteases such as macroglobulin. 17. The ophthalmic composition of claim 1 which contains neural factors such as substance P and insulin like growth factor. 18. The ophthalmic composition of claim 1 which contains antibacterial agents such as Ig G, lysozyme and complement. 19. The ophthalmic composition of claim 1 which contains long-chain fatty acids such as gadoleic, palmitic, palmitoleic, stearic, oleic, linoleic, arachidic, linolenic, eicosenoic, lignoceric, lactic and myristic acid. 20. The ophthalmic composition of claim 1 which contains hydrophilic lipids such as phospholipids, sphingomyelin, ceramides and cerebrosides. 21. Use, in accordance with the preceding claims, of these medicinal preparations in determined pathologies such as the case of dry eye syndrome.